COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Chinese mountain city Chongqing becomes world's new must-see
- Hong Kong inaugurates MTR Northern Link project to fast-track Northern Metropolis construction
- China issues orange alert as Typhoon Matmo approaches
- Xi, Bangladeshi president exchange congratulations on 50th anniversary of ties
- Vibrant China during holiday: Traditional culture meets tech
- China activates emergency response as Typhoon Matmo approaches
